CURRENT RECRUITING TRIALS

OAK (PD, MSA)

A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects with Primary Autonomic Failure

Primary Objectives:

The purpose of this study is to look at how safe TD9855 is when taken over a longer period of time (three and a half years) to treat symptomatic neurogenic orthostatic hypotension (symptomatic nOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being.

More information

NIO752 (PSP)

A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy

Currently, there is no approved medication to modify the progression of Progressive Supranuclear Palsy (PSP)

The Novartis CNIO752A02101 clinical trial is studying an investigational drug that may be able to slow or stop the worsening of Progressive Supranuclear Palsy.

  • Patients with PSP diagnosed within the last 5 years, aged 40 to 75 years old
  • Patients able to walk independently (5 steps) or with minimal assistance
  • History of falls within the last 12 months
  • Able to undergo medical procedures such as lumbar punctures and MRIs
  • The first part of the study can last up to 3 months, and the second part up to 9 months
  • There is no compensation for this study. However, costs related to participation in the study, such as travel and meals during visit days, will be reimbursed.
REASON (PD)

A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson’s Disease

Currently, there is no approved medication to modify the progression of Parkinson’s disease (PD).

The REASON (Biogen 254PD101) clinical trial is studying an investigational drug that may be able to slow or stop the worsening of PD.

  • Patients with PD diagnosed within the last 7 years, aged 35 to 80 years old
  • Currently taking 600mg or less of levodopa, or not taking any PD medications at all
  • Able to undergo medical procedures such as MRI
  • The first part of the study can last up to 5 months, and the second part up to 11 months
  • There is no compensation for this study. However, costs related to participation in the study, such as travel and meals during visit days, will be reimbursed.
SEQUOIA (PD, MSA, PAF)

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

The purpose of this study is to look at whether TD-9855 works and how safe when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on your general well-being and whether it can improve symptoms of neurogenic OH (nOH).

More information

PDBS (PD)

A multi-site longitudinal cohort study of Prodromal and Clinical Parkinson’s Disease

Parkinson’s disease (PD) develops slowly and is characterized by progressive and fluctuating motor changes. People with REM-sleep behavior disorder (RBD) are at risk of developing Parkinson’s disease in the future, and so may have mild motor changes. In general, it is difficult to monitor motor changes in Parkinson’s disease and REM sleep behavior disorder, because they can change from day to day.

Smartphones offer a potential solution to these challenges because they enable your motor state to be remotely and frequently monitored. The Roche PD Mobile Application v2 smartphone app combines active testing (small tests you do every day) with passive monitoring (the phone reading your mobility while you go about your day) to detect more subtle signs and symptoms of change.

The primary objective of this study is to determine whether data acquired from such a remote monitoring approach can reliably and validly identify and track motor and non-motor symptoms in REM sleep behavior disorder and clinical PD.

For this study, 230 male and female participants will be recruited across 4 groups, at approximately 6 sites in Canada.

For more information about upcoming or recruiting trials, contact Martin Chevrier

UPCOMING TRIALS

PADOVA (PD)

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson’s Disease

Currently, there is no approved medication to modify the progression of Parkinson’s disease (PD).

The PADOVA (Roche BN42358) clinical trial is studying the safety and efficacy of a drug for individuals with early Parkinson’s disease.

  • Aged 50 to 85, diagnosed with PD for at least 6 months and up to 3 years
  • Currently taking no more than 1 medication for PD (maximum daily dose of 450 mg of levodopa, 1 mg of rasagiline, or 10 mg of selegiline)
  • Able to undergo medical procedures such as MRI and DaTScans
  • Willing to use a smartphone application and smartwatch for the duration of the study
  • The study will last at least  76 weeks
  • There is no compensation for this study. However, costs related to participation in the study, such as travel and meals during visit days, will be reimbursed.
PPMI 2.0 (PD)

The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical – Establishing a Deeply Phenotyped PD Cohort

The purpose of this study is to obtain information from people with and without Parkinson disease (PD) so that researchers may better understand how Parkinson disease progresses, in order to inform better treatments.

More information